Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 20/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.76 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.76 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.76 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864820 | 0.92 | SLC16A1 (0.80) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864888 | 0.90 | SLC16A1 (0.78) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864629 | 0.88 | SLC16A1 (0.74) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864939 | 0.87 | SLC16A1 (1.00) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL29411933 | 0.87 | SLC16A1 (1.00) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL7504725 | 0.87 | SLC16A1 (0.79) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864834 | 0.86 | SLC16A1 (0.83) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864693 | 0.86 | SLC16A1 (0.80) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864661 | 0.86 | SLC16A1 (0.77) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864633 | 0.85 | SLC16A1 (0.84) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984644-B2 | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | claimed |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | ASTRAZENECA AB | 2003-10-09 | — | — | US | claimed |
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | ASTRAZENECA AB. | 2002-12-05 | — | — | US | claimed |
| US-6469014-B1 | IMMUNOSUPPRESSIVE ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | claimed |
| EP-0991653-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-16 | — | — | EP | claimed |
| US-6342502-B1 | ANTIASTHMATICS | ASTRAZENECA AB (GB) | 2002-01-29 | — | — | US | claimed |
| US-6180635-B1 | NOVEL THIENO(2,3-D)PYRIMIDINEDIONES WHICH EXHIBIT PHARMACOLOGICAL ACTIVITY, IN PARTICULAR IMMUNOSUPPRESSIVE ACTIVITY; TREATING ALLOGRAFT REJECTION | ASTRAZENECA UK LIMITED (GB) | 2001-01-30 | — | — | US | claimed |
| EP-0991653-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-04-12 | — | — | EP | claimed |
| WO-1998054190-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-12-03 | — | — | WO | claimed |
| US-6984644-B2 | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | ASTRAZENECA AB | 2003-10-09 | — | — | US | disclosed |
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | ASTRAZENECA AB. | 2002-12-05 | — | — | US | disclosed |
| US-6469014-B1 | IMMUNOSUPPRESSIVE ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | disclosed |
| EP-0991653-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-16 | — | — | EP | disclosed |
| US-6342502-B1 | ANTIASTHMATICS | ASTRAZENECA AB (GB) | 2002-01-29 | — | — | US | disclosed |
| US-6180635-B1 | NOVEL THIENO(2,3-D)PYRIMIDINEDIONES WHICH EXHIBIT PHARMACOLOGICAL ACTIVITY, IN PARTICULAR IMMUNOSUPPRESSIVE ACTIVITY; TREATING ALLOGRAFT REJECTION | ASTRAZENECA UK LIMITED (GB) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | TPMT, TSLP, TYMP | SLC16A1 3396/4885CYP2C9 976/4885MAPKAPK2 3712/4885 |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | TYMP, DPYD, TYMS | SLC16A1 4637/4885CYP2C9 363/4885MAPKAPK2 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.